首页> 外国专利> NEW LIGANDS WHICH ARE ACTIVATORS OF THE RAR RECEPTOR, USE IN HUMAN MEDICINE AND COSMETICS

NEW LIGANDS WHICH ARE ACTIVATORS OF THE RAR RECEPTOR, USE IN HUMAN MEDICINE AND COSMETICS

机译:是RAR受体激活剂的新药,在人类医学和化妆品中的使用

摘要

1-Oxyalkoxy-substituted biaryl-prop-2-yn-1-ol compounds (I) are new. 1-Oxyalkoxy-substituted biaryl-prop-2-yn-1-ol compounds of formula (I), their optical and geometric isomers and salts of (I; R 1= OH), are new. Ar : 1,4-phenylene (optionally monosubstituted by R 7), pyridinediyl, thiophenediyl or furandiyl; R 1H, T, NR'R'' or OR 8; T : 1-6C alkyl; R 2H or T; R 3H, T or COR 9; R 4 + R 5a group completing a fused 5- or 6-membered ring (optionally substituted by Me and optionally interrupted by O or S); R 6T or COR 10; R 71-20C alkyl, alkenyl, mono- or poly-hydroxyalkyl, aryl or aralkyl (both optionally substituted) or sugar, aminoacid or peptide residue; R 9, R 10CF 3 or T; R 11H, T or COR 12; R 12T; R', R'' : H, T, mono- or poly-hydroxyalkyl, optionally substituted aryl or sugar, aminoacid or peptide residue, or NR'R'' : heterocyclyl, and n : 2-6. [Image] ACTIVITY : Dermatological; Antiseborrheic; Antiinflammatory; Antiallergic; Immunosuppressive; Antipsoriatic; Antirheumatic; Cytostatic; Virucide; Ophthalmological; Vulnerary; Anorectic; Antilipemic; Antidiabetic; Antiarthritic; Endodrine-Gen.; Antiasthmatic; Neuroprotective; Cardiant; Antiarteriosclerotic; Hypotensive. MECHANISM OF ACTION : Retinoic acid receptor (RAR) activator. In RAR transactivation tests in vitro in HeLa cells, 4-(3-hydroxy-3-(4-(2-ethoxyethoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-prop-1-ynyl)-2-hydroxybenzoic acid (Ia) had K d (apparent) of 30 nM and AC 50 of 150 nM for RARalpha receptors, K d (apparent) of 120 nM and AC 50 of 100 nM for RARbeta receptors and K d (apparent) of 1 nM and AC 50 of 1 nM for RARgamma receptors.
机译:1-氧代烷氧基取代的联芳基-丙-2-炔-1-醇化合物(I)是新的。式(I)的1-氧代烷氧基取代的联芳基-丙-2-炔-1-醇化合物,它们的光学和几何异构体以及(I; R 1 = OH)的盐是新的。 Ar:1,4-亚苯基(任选被R 7单取代),吡啶二基,噻吩二基或呋喃二基; R 1H,T,NR'R''或OR 8; T:1-6C烷基; R 2H或T; R 3H,T或COR 9; R 4 + R 5a基团完成稠合的5或6元环(可选地由Me取代并且可选地由O或S间断); R 6T或COR 10; R 71-20C烷基,烯基,单或多羟基烷基,芳基或芳烷基(均被取代)或糖,氨基酸或肽残基; R 9,R 10CF 3或T; R 11H,T或COR 12; R 12T; R′,R″:H,T,单或多羟基烷基,任选取代的芳基或糖,氨基酸或肽残基,或NR′R″:杂环基,和n:2-6。 [图像]活动:皮肤病;抗脂溢性;消炎(药;抗过敏;免疫抑制对牛皮癣;抗风湿;细胞抑制杀病毒剂;眼科伤药;厌食的;抗血脂;抗糖尿病抗关节炎内分泌素抗哮喘具有神经保护作用;卡迪恩抗动脉硬化;低血压。作用机理:维甲酸受体(RAR)活化剂。在体外HeLa细胞的RAR反式激活测试中,4-(3-羟基-3-(4-(2-乙氧基乙氧基)-5,5,8,8-四甲基-5,6,7,8-四氢萘- 2-基)-丙-1-炔基)-2-羟基苯甲酸(Ia)的Kd(表观)为30 nM,AC 50为150 nM(对于RARalpha受体),K d(表观)为120 nM,AC 50对于RARbeta受体,为100 nM;对于RARgamma受体,K d(视在)为1 nM; AC 50为1 nM。

著录项

  • 公开/公告号AT432254T

    专利类型

  • 公开/公告日2009-06-15

    原文格式PDF

  • 申请/专利权人 GALDERMA RESEARCH & DEVELOPMENT;

    申请/专利号AT20040804395T

  • 发明设计人 BIADATTI THIBAUD;ARLABOSSE JEAN.MARIE;

    申请日2004-12-07

  • 分类号C07C65/28;C07C65/19;C07C69/003;C07C69/007;C07C69/63;C07C69/68;C07C69/76;C07C69/94;C07C235/42;C07C317/22;C07D213/79;C07D213/80;C07D295/192;C07D307/68;C07D307/87;C07D311/58;C07D311/64;C07D333/38;C07D333/40;C07D335/06;

  • 国家 AT

  • 入库时间 2022-08-21 19:24:26

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号